Ken Griffin Entrada Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 69,676 shares of TRDA stock, worth $975,464. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,676Holding current value
$975,464% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TRDA
# of Institutions
76Shares Held
25.7MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$68.1 Million0.87% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$62 Million25.58% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$61.7 Million22.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.75MShares$38.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.49MShares$20.8 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $439M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...